Earnings ·
BrainsWay reports $32.6M revenue, up 35%, as net profit rises 60% to $5.0 million for first half of 2026
BRSYFBrainsway Ltd.
BrainsWay Ltd. reported unaudited financial results for the six months ended June 30, 2026. Revenues increased 35% to $32.6 million from $24.2 million in the prior year period, driven by higher sales and lease volumes of Deep TMS systems. Net profit rose 60% to $5.0 million compared to $3.1 million previously. The company holds $62.1 million in cash and equivalents as of June 30, 2026. During the period, BrainsWay made strategic investments totaling approximately $10.1 million in financial assets measured at fair value through profit or loss, including a second tranche convertible loan to Neurolief and initial equity positions in Hopemark Health, BrainStim, Active Recovery TMS, and Radial Health. The company also noted potential revenue impacts from 15% U.S. tariffs on Israeli imports and regional geopolitical conflicts. BrainsWay Ltd. operates in the medical device industry, developing non-invasive neurostimulation treatments for mental health disorders.